WAYNE GOODMAN to Double-Blind Method
This is a "connection" page, showing publications WAYNE GOODMAN has written about Double-Blind Method.
Connection Strength
0.524
-
D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007 Jul; 22(4):230-7.
Score: 0.054
-
Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005 Aug; 87(2-3):161-7.
Score: 0.048
-
A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004 Mar 01; 55(5):553-5.
Score: 0.043
-
Deep Brain Stimulation for Depression Informed by Intracranial Recordings. Biol Psychiatry. 2022 08 01; 92(3):246-251.
Score: 0.037
-
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
Score: 0.033
-
Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2019 11 01; 176(11):931-938.
Score: 0.031
-
Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 1996 Mar; 11(1):21-9.
Score: 0.025
-
Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial. J Psychiatr Res. 2015 Dec; 71:140-7.
Score: 0.024
-
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015 Dec; 45(16):3571-80.
Score: 0.024
-
m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry. 1995 Aug 01; 38(3):138-49.
Score: 0.024
-
Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2013 Jun; 74(6):e527-32.
Score: 0.020
-
A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010 Dec 01; 68(11):1073-6.
Score: 0.017
-
Right and left dorsolateral pre-frontal rTMS treatment of refractory depression: a randomized, sham-controlled trial. Psychiatry Res. 2010 Aug 15; 178(3):467-74.
Score: 0.017
-
Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990 Jun; 47(6):577-85.
Score: 0.017
-
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989 Jan; 46(1):36-44.
Score: 0.015
-
Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases. Am J Psychiatry. 1986 Jul; 143(7):900-3.
Score: 0.013
-
A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003 Jun; 64(6):640-7.
Score: 0.010
-
Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol. 2001 Feb; 21(1):46-52.
Score: 0.009
-
Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1997 Sep; 154(9):1293-5.
Score: 0.007
-
Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry. 1997 May 01; 41(9):949-54.
Score: 0.007
-
A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biol Psychiatry. 1997 Jan 01; 41(1):117-21.
Score: 0.007
-
Effects of tryptophan depletion in panic disorder. Biol Psychiatry. 1994 Dec 01; 36(11):775-7.
Score: 0.006
-
A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994 Jul; 51(7):559-67.
Score: 0.006
-
Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994 Apr; 51(4):302-8.
Score: 0.005
-
Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994 Apr; 51(4):309-17.
Score: 0.005
-
The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol. 1993 Oct; 13(5):354-8.
Score: 0.005
-
Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1993 Apr; 150(4):647-9.
Score: 0.005
-
A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991 Jun; 11(3):175-84.
Score: 0.004
-
Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br J Psychiatry. 1990 Nov; 157:762-5.
Score: 0.004
-
Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1990; 26(3):279-84.
Score: 0.004